DDInter1609 DDInter1435
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Rivaroxaban {u} (Compound) resembles {v} (Compound) Linezolid
Rivaroxaban {u} (Compound) binds {v} (Gene) ABCB1
Rivaroxaban {u} (Compound) upregulates {v} (Gene) CDK6
Rivaroxaban {u} (Compound) downregulates {v} (Gene) GJA1
Rivaroxaban {u} (Compound) causes {v} (Side Effect) Pruritus
Rivaroxaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Rivaroxaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Rivaroxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Rivaroxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cimetidine
Rivaroxaban {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Rivaroxaban (Compound) resembles Linezolid (Compound)
Rivaroxaban (Compound) binds ABCB1 (Gene)
Rivaroxaban (Compound) upregulates CDK6 (Gene)
Rivaroxaban (Compound) downregulates GJA1 (Gene)
Rivaroxaban (Compound) causes Pruritus (Side Effect)
Rivaroxaban may cause a minor interaction that can limit clinical effects when taken with Chamomile
Rivaroxaban may cause a minor interaction that can limit clinical effects when taken with Modafinil
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Rivaroxaban may lead to a major life threatening interaction when taken with Regorafenib